The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities ...

Katherine Szarama, who has served as Prasad’s deputy at the Center for Biologics Evaluation and Research since December, joins a long list of temporary leaders at the Department of Health and Human ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...

GENEVA-- (BUSINESS WIRE)--Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see ...

After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers ...

Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for ...

The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...

UniQure plans to submit AMT-130 to the U.K.’s Medicines and Healthcare products Regulatory Agency in the third quarter of ...

Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to ...

Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t ...

Members of the FDA’s Oncologic Drugs Advisory Committee questioned AstraZeneca’s trial design of switching treatments earlier ...